Journal article icon

Journal article

Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial

Abstract:

Eosinophilic airway inflammation is often present in asthma, and reduction of such inflammation results in improved clinical outcomes. We hypothesised that fevipiprant (QAW039), an antagonist of prostaglandin D2 receptor 2, might reduce eosinophilic airway inflammation in patients with moderate-to-severe eosinophilic asthma.We performed a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial at Glenfield Hospital (Leicester, UK). We recruited patients with persiste...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1016/S2213-2600(16)30179-5

Authors


Expand authors...
Novartis Pharmaceuticals More from this funder
National Institute for Health Research More from this funder
Publisher:
Elsevier Publisher's website
Journal:
Lancet Respiratory Medicine Journal website
Volume:
4
Issue:
9
Pages:
699-707
Publication date:
2016-09-05
DOI:
EISSN:
2213-2619
ISSN:
2213-2600
Pubs id:
pubs:638767
URN:
uri:f07c58de-6462-4d8d-92c4-6960249f2623
UUID:
uuid:f07c58de-6462-4d8d-92c4-6960249f2623
Local pid:
pubs:638767
Paper number:
9
Language:
English
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP